|Application ||WB, IHC-P, E|
|Calculated MW||31674 Da|
|Antigen Region||163-193 aa|
|Other Names||Insulin-like growth factor-binding protein 3, IBP-3, IGF-binding protein 3, IGFBP-3, IGFBP3, IBP3|
|Target/Specificity||This IGFBP3 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 163-193 amino acids from the N-terminal region of human IGFBP3.|
|Format||Purified monoclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein G column, followed by dialysis against PBS.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||IGFBP3 Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||IGF-binding proteins prolong the half-life of the IGFs and have been shown to either inhibit or stimulate the growth promoting effects of the IGFs on cell culture. They alter the interaction of IGFs with their cell surface receptors. Also exhibits IGF-independent antiproliferative and apoptotic effects mediated by its receptor TMEM219/IGFBP-3R.|
|Tissue Location||Expressed by most tissues. Present in plasma.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
IGFBP3 is a member of the insulin-like growth factor binding protein (IGFBP) family with an IGFBP domain and a thyroglobulin type-I domain. The protein forms a ternary complex with insulin-like growth factor acid-labile subunit (IGFALS) and either insulin-like growth factor (IGF) I or II. In this form, it circulates in the plasma, prolonging the half-life of IGFs and altering their interaction with cell surface receptors.
Muzumdar,R.H., Diabetes 55 (10), 2788-2796 (2006)
Novosyadlyy,R., Growth Horm. IGF Res. 15 (5), 313-323 (2005)
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.